SUBSCRIBE
SUBSCRIBE

Vertex Pharmaceuticals

NEWS
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Vertex’s Profitability Hints It May Be Shopping Soon
November 4, 2015
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Policy
Feds Subpoena Vertex Documents Regarding Laboratory Practices
November 2, 2015
 · 
3 min read
Business
Vertex Coughs Up $105 Million Upfront to CRISPR for Gene Editing Pact
October 26, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Genetown
Vertex’s Success Spurs Startups Corbus and Pulmatrix to Enter Cystic Fibrosis Market
August 18, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Job Trends
Vertex Renegotiates Tax Deal With City of Boston, Ready to Rebound and Start Hiring
August 12, 2015
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Deals
Watch Out Gilead, Investors Feel Vertex May Be Biogen’s Good Fit
July 31, 2015
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Business
Ex-Vertex Digs Get Two New Biotech Tenants in CRISPR and Synologic
July 30, 2015
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Deals
Four Boston Biotechs That Could Make M&A Moves This Year
July 30, 2015
 · 
3 min read
Genetown
The Secret To Vertex’ Success
July 29, 2015
 · 
1 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Business
Vertex Reports First Quarter 2015 Financial Results
April 30, 2015
 · 
1 min read
Business
Vertex To Announce First Quarter 2015 Financial Results On April 29
April 10, 2015
 · 
1 min read
Drug Development
Vertex Announces Data From 12-Week Phase 2 Safety Study Of VX-661 In Combination With Ivacaftor In People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation
March 23, 2015
 · 
15 min read
FDA
Vertex Receives U.S. FDA Approval Of KALYDECO (Ivacaftor) For Children With Cystic Fibrosis Ages 2 To 5 Who Have Specific Mutations In The CFTR Gene
March 18, 2015
 · 
8 min read
Biotech Bay
BioSpace Temperature Poll: After Vertex Pulls Up Stakes, Will Boston See a Biotech Exodus?
March 6, 2015
 · 
1 min read
Drug Development
Tiny Startup Spyryx Looks to One-Up Vertex Pharmaceuticals (MA) With One-Size-Fits-All Cystic Fibrosis Therapy
February 13, 2015
 · 
1 min read
FDA
Vertex Pharmaceuticals (MA) Release: FDA Approves KALYDECO® (Ivacaftor) For Use In People With Cystic Fibrosis Ages 6 And Older Who Have The R117H Mutation
December 30, 2014
 · 
8 min read
Genetown
Vertex Pharmaceuticals (MA) To Present At Deutsche Bank BioFEST On December 2
November 21, 2014
 · 
1 min read
Policy
Vertex Pharmaceuticals (MA) Submits Applications In The U.S. And Europe For Approval Of Lumacaftor In Combination With Ivacaftor For People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation
November 5, 2014
 · 
8 min read
Business
Vertex Pharmaceuticals (MA) To Announce Third Quarter 2014 Financial Results On October 28
October 15, 2014
 · 
1 min read
Load More